Clearing the amyloid in Alzheimer's

progress towards earlier diagnosis and effective treatments - an update for clinicians

Prita R. Asih, Pratishtha Chatterjee, Giuseppe Verdile, Veer B. Gupta, Robert D. Trengove, Ralph N. Martins

Research output: Contribution to journalReview article

11 Citations (Scopus)


A beta (Aβ or β-amyloid) is a key molecule in Alzheimer's disease (AD) pathogenesis. According to the 'amyloid hypothesis', the gradual accumulation of Aβ triggers events which results in neuronal loss in regions of the brain involved with memory and learning. Diverse agents have been developed to reduce brain Aβ accumulation or to enhance its clearance. Some have progressed to human trials, however all have failed to improve cognition in patients. This has led researchers to question whether Aβ is really the problem. However, the trials have been targeting end stages of AD, by which stage extensive irreversible neuronal damage has already occurred. Intervention is required preclinically, therefore preclinical AD biomarkers are needed. In this regard, amyloid imaging and cerebrospinal fluid biomarkers are leading the way, with plasma biomarkers and eye tests also being investigated. This review covers the current state of knowledge of Aβ as an early diagnostic biomarker and as a therapeutic target in AD.

Original languageEnglish
Pages (from-to)363-378
Number of pages16
JournalNeurodegenerative Disease Management
Issue number5
Publication statusPublished - Oct 2014
Externally publishedYes


  • amyloid
  • anti-amyloid drug
  • biomarkers
  • CSF
  • lifestyle
  • PET amyloid imaging plasma biomarkers
  • retinal photography
  • Type 2 diabetes

Fingerprint Dive into the research topics of 'Clearing the amyloid in Alzheimer's: progress towards earlier diagnosis and effective treatments - an update for clinicians'. Together they form a unique fingerprint.

  • Cite this